9,2937,2052,08829%Assays and related products
(13,487)(3,838)(9,649)-251%Total Operating income (loss)
(4,194)3,367(7,561)-225%Nine Months EndedSeptember 30,Variance20132012($)(%)(unaudited)RevenueTechnology and strategic partnerships
$96,352$91,358$ 4,9945%Assays and related products
158,267147,04711,2208%Operating income (loss)Technology and strategic partnerships
23,36821,7251,6438%Assays and related products
(24,073)(6,264)(17,809)-284%Total Operating income (loss)
(705)15,461(16,166)-105%FINANCIAL OUTLOOK AND GUIDANCE The Company has revised its 2013 annual revenue guidance to a range of between $212 and $217 million from $220 and $230 million.
CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2013, at 4:00 p.m. CST/5:00 p.m. EST, Monday, November 4, 2013. The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link. Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.
Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as
|SOURCE Luminex Corporation|
Copyright©2012 PR Newswire.
All rights reserved